drugset / Trial / NCT06494397

Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions

NCT06494397

Phase 1 Completed 26 enrolled Vanda Pharmaceuticals
RandomizedCrossoverOpen-labelTreatment

Summary

Study to compare the pharmacokinetics and pharmacodynamics of VHX-896 and iloperidone and evaluate the safety and tolerability of VHX-896 and iloperidone in patients with schizophrenia or bipolar I disorder under steady state conditions.

Timeline

Start
2024-07-11
Primary completion
2024-10-24
Completion
2024-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule 12 mg Oral
Subject VHX-896 Unknown 12 mg Oral